» Articles » PMID: 22723721

Development of an Experimental Protocol for Uptake Studies of Metal Compounds in Adherent Tumor Cells

Overview
Date 2012 Jun 23
PMID 22723721
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Cellular uptake is being widely investigated in the context of diverse biological activities of metal compounds on the cellular level. However, the applied techniques differ considerably, and a validated methodology is not at hand. Therefore, we have varied numerous aspects of sample preparation of the human colon carcinoma cell line SW480 exposed in vitro to the tumor-inhibiting metal complexes cisplatin and indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(iii)] (KP1019) prior to analysis with ICP-MS, and the results were found to be tremendously influenced by adsorption to the culture dishes. Adsorption to culture plates increases linearly with the concentration of KP1019, depends on the protein content of the medium, the duration of contact to protein-containing medium prior to drug addition and the hydrophilicity/lipophilicity of the compound. For varying degrees of cell confluence, adsorption of Ru hardly differs from cell-free experiments. Desorption from the plates contributes to total Ru detected in dependence on the cell harvesting method. Desorption kinetics for lysis in HNO(3) and tetramethylammonium hydroxide (TMAH) are comparable, but TMAH is a more potent desorbant. Sample storage conditions prior to analysis influence significantly the recovery of analyte. Protocols using cell lysis in the culture plate without proper corrections run the risk of producing artefacts resulting from metal adsorption/desorption to an extent comparable with the actual cellular content. However, experimental protocols reported in the literature frequently do not contain information whether adsorption or blank correction were performed and should be regarded with caution, especially if lysis was performed directly in the culture dishes.

Citing Articles

Recent Advances on Pt-Based Compounds for Theranostic Applications.

Ferrari G, Lopez-Martinez I, Wanek T, Kuntner C, Montagner D Molecules. 2024; 29(15).

PMID: 39124859 PMC: 11313463. DOI: 10.3390/molecules29153453.


In vitro and in vivo accumulation of the anticancer Ru complexes [Ru(cym)(HQ)Cl] and [Ru(cym)(PCA)Cl]Cl.

Riisom M, Morrow S, Herbert C, Tremlett W, Astin J, Jamieson S J Biol Inorg Chem. 2023; 28(8):767-775.

PMID: 37962611 DOI: 10.1007/s00775-023-02026-w.


Investigation of the Impact of L-Phenylalanine and L-Tyrosine Pre-Treatment on the Uptake of 4-Borono-L-Phenylalanine in Cancerous and Normal Cells Using an Analytical Approach Based on SC-ICP-MS.

Balcer E, Giebultowicz J, Sochacka M, Ruszczynska A, Muszynska M, Bulska E Molecules. 2023; 28(18).

PMID: 37764328 PMC: 10534874. DOI: 10.3390/molecules28186552.


The Lipid Metabolism as Target and Modulator of BOLD-100 Anticancer Activity: Crosstalk with Histone Acetylation.

Baier D, Mendrina T, Schoenhacker-Alte B, Pirker C, Mohr T, Rusz M Adv Sci (Weinh). 2023; 10(32):e2301939.

PMID: 37752764 PMC: 10646284. DOI: 10.1002/advs.202301939.


The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation.

Baier D, Schoenhacker-Alte B, Rusz M, Pirker C, Mohr T, Mendrina T Pharmaceutics. 2022; 14(2).

PMID: 35213972 PMC: 8875291. DOI: 10.3390/pharmaceutics14020238.


References
1.
Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

2.
Jakupec M, Galanski M, Arion V, Hartinger C, Keppler B . Antitumour metal compounds: more than theme and variations. Dalton Trans. 2007; (2):183-94. DOI: 10.1039/b712656p. View

3.
Martelli L, Di Mario F, Ragazzi E, Apostoli P, Leone R, Perego P . Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochem Pharmacol. 2006; 72(6):693-700. DOI: 10.1016/j.bcp.2006.06.008. View

4.
Groessl M, Hartinger C, Polec-Pawlak K, Jarosz M, Dyson P, Keppler B . Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication. Chem Biodivers. 2008; 5(8):1609-1614. DOI: 10.1002/cbdv.200890148. View

5.
Bergamo A, Sava G . Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans. 2007; (13):1267-72. DOI: 10.1039/b617769g. View